

## Calquence Tabs - (Eq 100 mg Base ; Tablet)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Acalabrutinib Maleate  | <b>Innovator</b>            | Astrazeneca         |
| <b>Dosage</b>                | Eq 100 mg Base ; Tablet  | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5  | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with: • Mantle cell lymphoma (MCL) who have received at least one prior therapy. • Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.